相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Development of a Novel Long-Lived ImmunoPET Tracer for Monitoring Lymphoma Therapy in a Humanized Transgenic Mouse Model
Arutselvan Natarajan et al.
BIOCONJUGATE CHEMISTRY (2012)
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET
Saiyada N. F. Rizvi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Positron Emission Tomography of 64Cu-DOTA-Rituximab in a Transgenic Mouse Model Expressing Human CD20 for Clinical Translation to Image NHL
Arutselvan Natarajan et al.
MOLECULAR IMAGING AND BIOLOGY (2012)
RADAR Commentary: Evolution and Current Status of Dosimetry in Nuclear Medicine
Michael G. Stabin et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
RADAR Realistic Animal Model Series for Dose Assessment
Mary A. Keenan et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies)
Tove Olafsen et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
In vivo molecular imaging of experimental joint inflammation by combined F-18-FDG positron emission tomography and computed tomography
Ingo M. Irmler et al.
ARTHRITIS RESEARCH & THERAPY (2010)
A recovery coefficient method for partial volume correction of PET images
Shyam M. Srinivas et al.
ANNALS OF NUCLEAR MEDICINE (2009)
Radioimmunoimaging with Longer-Lived Positron-Emitting Radionuclides: Potentials and Challenges
Tapan K. Nayak et al.
BIOCONJUGATE CHEMISTRY (2009)
MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for 111In- and 90Y-Ibritumomab Tiuxetan
Darrell R. Fisher et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Recombinant Anti-CD20 Antibody Fragments for Small-Animal PET Imaging of B-Cell Lymphomas
Tove Olafsen et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy
Xuhui Zhou et al.
ONCOLOGIST (2008)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-PET with 67gallium scintigraphy in the evaluation of lymphoma -: Relation to histologic subtypes-based on the World Health Organization Classification
Norifumi Tsukamoto et al.
CANCER (2007)
Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies
Rakesh Dixit et al.
DRUG DISCOVERY TODAY (2007)
Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography
Lars R. Perk et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2006)
Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas
Maroun Karam et al.
CANCER (2006)
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma
A Nademanee et al.
BLOOD (2005)
131I-tositumomab therapy as initial treatment for follicular lymphoma
MS Kaminski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma
JN Winter
CLINICAL LYMPHOMA (2004)
Physical models and dose factors for use in internal dose assessment
MG Stabin et al.
HEALTH PHYSICS (2003)
Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma:: chemotherapy versus chemotherapy plus rituximab
M Herold et al.
ANNALS OF HEMATOLOGY (2003)
Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma
GA Wiseman et al.
CANCER (2002)
分享论文
